Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10510MR)

This product GTTS-WQ10510MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10510MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14242MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ14341MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ4043MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ290MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ14280MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RG7155
GTTS-WQ15323MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ13175MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ13057MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW